Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer

ClinicalTrials.gov ID: NCT00073307

Public ClinicalTrials.gov record NCT00073307. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 7:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer.

Study identification

NCT ID: NCT00073307
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bayer; Industry
Enrollment: 903 participants

Conditions and interventions

Conditions

Carcinoma, Renal Cell

Interventions

Sorafenib (Nexavar, BAY43-9006) Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 31, 2003
Primary completion: Aug 31, 2006
Completion: Mar 31, 2010
Last update posted: Feb 5, 2014

2003 – 2010

United States locations

U.S. sites: 31
U.S. states: 22
U.S. cities: 30

Facility	City	State	ZIP	Site status
Not listed	Tucson	Arizona	85712	—
Not listed	Los Angeles	California	90033	—
Not listed	Los Angeles	California	90057	—
Not listed	Sacramento	California	95817	—
Not listed	Aurora	Colorado	80045	—
Not listed	Hamden	Connecticut	06518	—
Not listed	Atlanta	Georgia	30309	—
Not listed	Chicago	Illinois	60637	—
Not listed	Louisville	Kentucky	40202	—
Not listed	Lafayette	Louisiana	70506	—
Not listed	Frederick	Maryland	21701	—
Not listed	Boston	Massachusetts	02215	—
Not listed	Minneapolis	Minnesota	55455	—
Not listed	Columbia	Missouri	65203-3244	—
Not listed	St Louis	Missouri	63110-1093	—
Not listed	Brooklyn	New York	11220	—
Not listed	New York	New York	10032	—
Not listed	The Bronx	New York	10466-2604	—
Not listed	Canton	Ohio	44718	—
Not listed	Cleveland	Ohio	44195	—
Not listed	Dayton	Ohio	45429	—
Not listed	Portland	Oregon	97239	—
Not listed	Philadelphia	Pennsylvania	19107-5096	—
Not listed	Spartanburg	South Carolina	29303	—
Not listed	Dallas	Texas	75246	—
Not listed	Laredo	Texas	78041	—
Not listed	San Antonio	Texas	78212	—
Not listed	Salt Lake City	Utah	84132	—
Not listed	Richmond	Virginia	23229	—
Not listed	Seattle	Washington	98101	—
Not listed	Milwaukee	Wisconsin	53226-3596	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 90 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00073307, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 5, 2014 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00073307 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →